ERBB2 and neoplasm: By applying mass spectrometry or affinity-based assays to tumor tissue, plasma, or enriched exosomes, clinicians can identify overexpressed receptor tyrosine kinases (e.g., EGFR, HER2) or activated signaling nodes (e.g., phosphorylated AKT, ERK) that constitute actionable targets [90].